Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)

Phase 3TerminatedNCT00738972

Fundación Lindavista del Corazón AC12 enrolled

Overview

Evaluate pleiotropic effects of simvastatin in hypertensive patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hypertension

Interventions

valsartanDRUG

80 mg valsartan. Duration: 12 months. Tablets

pravastatinDRUG

40 mg pravastatin. Duration: 12 months. Tablets

simvastatinDRUG

40 mg simvastatin. Duration: 12 months. Tablets

ezetimibe (+) simvastatin

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Females Or Males Over 18 Years Old * Patients With Systemic Arterial Hypertension Grade I And II According With The European Society Of Cardiology * Left Ventricular hypertrophy Demonstrated By Echocardiography * Mild To Moderated hypercholesterolemia * Willing To Participate And Sign The Informed Consent Form (ICF) Exclusion Criteria: * Type 1 Or 2 Diabetes Mellitus * Familiar hypercholesterolemia * Low Density Lipoprotein-Cholesterol (LDL-C) \> 190 mg/dl * History Of Myocardial Infarction Or Stable Chronic Angina * Triglycerides \>250 mg/dl

Outcomes

Primary Outcomes

Left Ventricular Hypertrophy Reduction With Statins in Hypertensive Patients

Left ventricular hypertrophy reduction was to be measured by echocardiography.

Time frame: 6 Month(s)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.